# MINDY2

## Overview
MINDY2 is a gene that encodes the protein MINDY lysine 48 deubiquitinase 2, a deubiquitinating enzyme involved in the regulation of protein degradation. This enzyme specifically targets lysine 48-linked polyubiquitin chains, playing a critical role in maintaining protein turnover and cellular homeostasis by influencing proteasomal degradation pathways (Lange2023Comprehensive). MINDY2 is predominantly active in the cytoplasm, where it contributes to the stability of proteins and the regulation of various cellular signaling pathways. The enzyme's ability to process both branched and unbranched ubiquitin chains underscores its importance in cellular protein regulation (Lange2023Comprehensive). MINDY2's involvement in disease contexts, such as cancer and ischemic heart conditions, highlights its potential as a therapeutic target, with its expression levels correlating with disease progression and prognosis (Liu2023The; Kanapeckaitė2021Insights).

## Structure


## Function
MINDY2 (MINDY lysine 48 deubiquitinase 2) is a deubiquitinating enzyme that plays a crucial role in the regulation of protein degradation by removing ubiquitin from lysine 48-linked polyubiquitin chains. This activity is essential for maintaining protein turnover and cellular homeostasis, as it influences the degradation of proteins by the proteasome (Lange2023Comprehensive). MINDY2 is active in the cytoplasm, where it contributes to the stability of proteins and the regulation of cellular signaling pathways. Its consistent activity across different ubiquitin chain types suggests a role in maintaining ubiquitin chain homeostasis within cells (Lange2023Comprehensive).

In the context of ischemic heart conditions, MINDY2 is involved in processes related to cell proliferation, immune signaling, and protein turnover. It is downregulated in ischemic conditions, indicating its potential involvement in inflammatory processes (Kanapeckaitė2021Insights). This suggests that MINDY2 may have a role in modulating cellular responses to stress and injury, although its specific functions in healthy human cells require further investigation. The enzyme's activity in processing both branched and unbranched ubiquitin chains highlights its importance in cellular protein regulation (Lange2023Comprehensive).

## Clinical Significance
MINDY2 has been implicated in several diseases due to its role in protein degradation and cellular processes. In pancreatic cancer (PC), MINDY2 is overexpressed, correlating with poor prognosis and aggressive disease characteristics. Its elevated expression is associated with advanced tumor stages, metastasis, and reduced overall survival. MINDY2 promotes PC proliferation and metastasis by stabilizing actinin alpha 4 (ACTN4) and activating the PI3K/AKT/mTOR signaling pathway, which enhances cancer cell viability and invasion (Liu2023The).

In breast cancer, MINDY2 is part of a deubiquitinating enzyme-related index (DUBRI) used to predict prognosis and treatment response. Higher DUBRI scores, which include MINDY2 expression, are linked to worse overall survival and increased immune cell infiltration, suggesting a role in the tumor microenvironment and potential implications for immunotherapy (Deng2024The).

MINDY2 is also mentioned in the context of Alzheimer's disease, where it is upregulated in the female cortex, potentially contributing to disease susceptibility. Its expression is influenced by miRNA MIR219A2, which may offer a protective effect by repressing MINDY2 in males (Fass2024Relationship).

## Interactions
MINDY2, a deubiquitinating enzyme, is known to interact with actinin alpha 4 (ACTN4) in pancreatic cancer cells. This interaction is crucial for the stabilization of ACTN4 protein levels, as MINDY2 removes K48-linked ubiquitin chains from ACTN4, preventing its proteasomal degradation. The stabilization of ACTN4 by MINDY2 is significant because it activates the PI3K/AKT/mTOR signaling pathway, which is essential for pancreatic cancer proliferation and metastasis (Liu2023The).

The interaction between MINDY2 and ACTN4 highlights the enzyme's role in promoting cancer cell viability, proliferation, and metastasis. Silencing ACTN4 has been shown to reverse the pro-carcinogenic effects of MINDY2, underscoring the importance of this interaction in the progression of pancreatic cancer (Liu2023The).

MINDY2's involvement in immune cell infiltration and its association with immune checkpoint-related genes suggest potential interactions with components of the immune system, although specific protein interactions in this context are not detailed (Liu2023The). These interactions position MINDY2 as a potential therapeutic target in cancer treatment strategies.


## References


[1. (Fass2024Relationship) Stuart B. Fass, Bernard Mulvey, Rebecca Chase, Wei Yang, Din Selmanovic, Sneha M. Chaturvedi, Eric Tycksen, Lauren A. Weiss, and Joseph D. Dougherty. Relationship between sex biases in gene expression and sex biases in autism and alzheimer’s disease. Biology of Sex Differences, June 2024. URL: http://dx.doi.org/10.1186/s13293-024-00622-2, doi:10.1186/s13293-024-00622-2. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13293-024-00622-2)

[2. (Liu2023The) Peng Liu, Songbai Liu, Changhao Zhu, Yongning Li, Ying Li, Xiaobin Fei, Junyi Hou, Xing Wang, and Yaozhen Pan. The deubiquitinating enzyme mindy2 promotes pancreatic cancer proliferation and metastasis by stabilizing actn4 expression and activating the pi3k/akt/mtor signaling pathway. Frontiers in Oncology, May 2023. URL: http://dx.doi.org/10.3389/fonc.2023.1169833, doi:10.3389/fonc.2023.1169833. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2023.1169833)

[3. (Deng2024The) Youyuan Deng, Jingyong Li, Ye He, Dou Du, Zhiya Hu, Chao Zhang, Qishuo Rao, Yiping Xu, Jianguo Wang, and Ke Xu. The deubiquitinating enzymes-related signature predicts the prognosis and immunotherapy response in breast cancer. Aging, July 2024. URL: http://dx.doi.org/10.18632/aging.206010, doi:10.18632/aging.206010. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.18632/aging.206010)

[4. (Kanapeckaitė2021Insights) Austė Kanapeckaitė and Neringa Burokienė. Insights into therapeutic targets and biomarkers using integrated multi-‘omics’ approaches for dilated and ischemic cardiomyopathies. Integrative Biology, 13(5):121–137, May 2021. URL: http://dx.doi.org/10.1093/intbio/zyab007, doi:10.1093/intbio/zyab007. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/intbio/zyab007)

5. (Lange2023Comprehensive) Comprehensive approach to study branched ubiquitin chains reveals roles for K48-K63 branches in VCP/p97-related processes. This article has 10 citations.